[Clinico-pharmacologic aspects of cardioactive drugs].
Erdmann
E
E
Medizinische Klinik, Universität zu Köln.
Schwinger
R H
RH
Böhm
M
M
D000818:Animals; D002120:Calcium Channel Agonists / Q000009:adverse effects / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000009:adverse effects / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002395:Catecholamines / Q000009:adverse effects / Q000627:therapeutic use; D000242:Cyclic AMP / Q000378:metabolism; D006331:Heart Diseases / Q000188:drug therapy* / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D015222:Sodium Channels / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D002120:Calcium Channel Agonists; D002301:Cardiac Glycosides; D002317:Cardiovascular Agents; D002395:Catecholamines; D010726:Phosphodiesterase Inhibitors; D011804:Quinolines; D015222:Sodium Channels; D014665:Vasodilator Agents; C047316:flosequinan; D000242:Cyclic AMP
Klinisch-pharmakologische Aspekte kardioaktiver Pharmaka.